Ubrogepant Efficacy and Safety in the Treatment of Acute Migraine in Patients Currently Treated With CGRP Monoclonal Antibodies (CGRPmAbs)
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 164
- 试验地点
- 1
- 主要终点
- Pain freedom
研究概览
简要总结
This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.
详细描述
The purpose of this study is to examine the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). There are currently very limited data available about the use of CGRP receptor antagonists in this population, resulting in difficulty obtaining prior authorization to use ubrogepant in patients currently treated with CGRPmAbs. Questions remain as to whether these patients, whose CGRP or CGRP receptors are suppressed, will experience the same safety and efficacy results as patients without such suppression by CGRPmAbs.
This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.
Primary Objective:
To evaluate the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality).
Primary Endpoint:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female patients ages 18 to 75 years, at screening (Visit 1).
- •At least a 1-year history of migraine with or without aura.
- •History of ≥3 monthly headache days of at least moderate severity.
- •Study patient currently on CGRPmAbs must be on treatment > 1 month at screening.
- •By history, the patient's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom
排除标准
- •History of <3 monthly headache days of at least moderate severity
- •Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John's Wort)
- •Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
- •Currently on Botox treatment for CM.
- •Concomitant use of gepants as a preventative treatment.
- •Current user of illicit drugs, or a history within 1 year prior to screening (visit 1) of drug or alcohol abuse or dependence
- •Clinically significant hematologic, endocrine, cardiovascular, pulmonary, gastrointestinal, or neurologic disease. If there is a history of such a disease, but the condition has been stable for more than 1 year prior to screening (visit 1) and is judged by the PI as not likely to interfere with participation in the study, the participant may be included.
- •Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating.
研究组 & 干预措施
w/o CGRPmAb
w/o CGRPmAb
干预措施: Ubrogepant 50 MG [Ubrelvy] (Drug)
w/o CGRPmAb
w/o CGRPmAb
干预措施: Ubrogepant 100 MG [Ubrelvy] (Drug)
Tx w/ CGRPmAb
Tx w/ CGRPmAb
干预措施: Ubrogepant 50 MG [Ubrelvy] (Drug)
Tx w/ CGRPmAb
Tx w/ CGRPmAb
干预措施: Ubrogepant 100 MG [Ubrelvy] (Drug)
结局指标
主要结局
Pain freedom
时间窗: 2 hours post treatment
Pain freedom at 2 hours.
Freedom from most bothersome symptom
时间窗: 2 hours post treatment
Freedom from most bothersome symptom at 2 hours.
次要结局
- Percentage of patients with sustained pain relief from 2-24 hours after initial dose.(2-24 hours after initial dose)
- Pain relief at 2 hours after 2nd dose(2 hours after 2nd dose)
- Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose.(2-24 hours after 2nd dose)
- Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose.(2-24 hours after 2nd dose)
- Pain relief at 2 hours(2 hours post treatment)
- Percentage of patients with sustained pain freedom from 2-24 hours after initial dose.(2-24 hours after initial dose)
研究者
Bradley Torphy, MD
Managing Director
Chicago Headache Center & Research Institute